Anuh Pharma Limited shareholders approved a final dividend of ₹1.50 per equity share of face value ₹5 each for FY26 during the company’s 66th Annual General Meeting (AGM). The meeting was conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM) on August 12, 2026, in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The AGM commenced at 4:00 pm and concluded at 5:12 pm, with 45 members attending. Mr. Arun L. Todarwal, Chairman, presided over the proceedings after ascertaining the requisite quorum. Mr. Bipin N. Shah, Vice Chairman, welcomed the shareholders, while Mr. Manan J. Vadhan, Company Secretary and Compliance Officer, managed the procedural aspects.

Voting Participation and Results

The scrutinizer report dated August 14, 2026, reveals that 72.22% of the total outstanding shares (100,224,000) were polled, amounting to 72,378,520 votes. Promoters and promoter group shareholders, holding 71,956,044 shares, accounted for 99.79% of their holdings in the vote count. Public non-institutional shareholders polled 2.03% of their holdings, while public institutions polled 3.17%.

Key Resolutions Approved

Shareholders voted on several ordinary and special business items. The ordinary business included the adoption of audited financial statements for the year ended March 31, 2026, alongside the declaration of the dividend.

The board proposed the reappointment of two directors retiring by rotation under Section 152(6) of the Companies Act, 2013:

• Mr. Bipin N. Shah (DIN: 00083244), a Chemical Engineer and Vice Chairman with nearly 50 years of experience in the pharmaceutical field.
• Mr. Arun L. Todarwal (DIN: 00020916), a Fellow Member of the Institute of Chartered Accountants of India practicing since 1981.

Additionally, the meeting ratified the remuneration of Mr. Ankit Kishor Chande as Cost Auditor for the financial year ending March 2027. Mr. Chande, a Qualified Cost Accountant with over 12 years of experience, has served industries including pharmaceuticals and chemicals.

Special Business Items

Under special business, shareholders considered revisions to the remuneration payable to the Joint Managing Directors for FY27:

• Mr. Ritesh B. Shah (DIN: 02496729)
• Mr. Vivek B. Shah (DIN: 02878724)

The agenda also included the adoption of a new set of Memorandum of Association and alterations to the Articles of Association, both aligned with the provisions of the Companies Act, 2013. All special resolutions passed with overwhelming support from promoter shareholders, though some dissent was noted from public non-institutional voters on remuneration revisions.

Voting Process

The company facilitated remote e-voting from August 9, 2026, at 9:00 am to August 11, 2026, at 5:00 pm. Members present at the virtual meeting who had not voted remotely were allowed to cast their votes electronically via the VC platform. Mr. Pramod S. Shah, Partner at M/s. Pramod S. Shah & Associates, served as the Scrutinizer to ensure fair and transparent voting procedures.

Mr. Darshan Rampariya, Chief Financial Officer, presented the Key Audit Points from the Auditors’ report for FY26. During the session, Joint Managing Director Mr. Ritesh B. Shah addressed member queries regarding the company’s accounts and business operations.

Anuh Pharma Limited reported a net profit after tax of ₹1,142.49 lakh for the quarter ended June 30, 2026, marking a 37.6% year-on-year increase from ₹830.12 lakh in Q1FY26. The improvement in profitability was primarily driven by an expansion in EBITDA margin, which widened to 9.47% from 7.34% in the prior year period, even as revenue from operations grew modestly by 3.9% to ₹19,381.04 lakh. This divergence between top-line and bottom-line growth highlights improved operational efficiency during the quarter.

The Board of Directors approved the unaudited standalone financial results on August 7, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subjected to a limited review by the statutory auditors, Jayantilal Thakkar & Co. Dilip J. Thakkar, Partner at Jayantilal Thakkar & Co., issued the independent auditor's review report confirming that the statement discloses information required under the Listing Regulations. The company also published advertisements regarding these results in Financial Express (English) and Mumbai Lakshdeep (Marathi) on August 9, 2026, as per Regulation 47.

Financial Performance Highlights

The following table summarises the key financial metrics for the quarter under review compared to the prior year period:

Corporate Developments

In addition to the financial results, the Board addressed shareholding pattern disclosures. Three members of the Promoter Group — Vikram Kirtilal Shah, Kiran Piyush Shah, and Kinjal Siddharth Jhaveri — withdrew their earlier applications for reclassification from the 'Promoter' category to the 'Public' category under Regulation 31A of the SEBI LODR Regulations, 2015. These shareholders will continue to be classified as part of the Promoter Group. Collectively, they hold 8,31,748 equity shares, representing 0.83% of the total shareholding.

The company also adopted a revised Policy on Related Party Transactions during the meeting, which is available on its website. All per-share figures in the financial results reflect the impact of the 1:1 bonus share issuance approved by shareholders in September 2025 and allotted on July 16, 2025. The paid-up equity share capital stands at ₹5,011.20 lakh following the bonus issue.